Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5218)
All Articles published online
|
Publishing Process of This Article
|
Apr 27, 2021 (publication date) through Oct 2, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Alamoudi JA, Li W, Gautam N, Olivera M, Meza J, Mukherjee S, Alnouti Y. Bile acid indices as biomarkers for liver diseases I: Diagnostic markers. World J Hepatol 2021; 13(4): 433-455 [PMID: 33959226 DOI: 10.4254/wjh.v13.i4.433] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v13/i4/433.htm |
| Number | Citing Articles |
| 1 |
Sayed Obaidullah Aseem, Phillip B. Hylemon, Huiping Zhou. Bile Acids and Biliary Fibrosis. Cells 2023; 12(5): 792 doi: 10.3390/cells12050792
|
| 2 |
Rulaiha Taylor, Veronia Basaly, Bo Kong, Ill Yang, Anita M Brinker, Gina Capece, Anisha Bhattacharya, Zakiyah R Henry, Katherine Otersen, Zhenning Yang, Vik Meadows, Stephanie Mera, Laurie B Joseph, Peihong Zhou, Lauren M Aleksunes, Troy Roepke, Brian Buckley, Grace L Guo. Effects of therapeutically approved individual bile acids on the development of metabolic dysfunction-associated steatohepatitis a low bile acid mouse model. Toxicological Sciences 2024; doi: 10.1093/toxsci/kfae110
|
| 3 |
Wenkuan Li, Jawaher Abdullah Alamoudi, Nagsen Gautam, Devendra Kumar, Macro Olivera, Yeongjin Gwon, Sandeep Mukgerjee, Yazen Alnouti, Amal Santra. Urinary BA Indices as Prognostic Biomarkers for Complications Associated with Liver Diseases. International Journal of Hepatology 2022; 2022: 1 doi: 10.1155/2022/5473752
|
| 4 |
Harry Sutton, Ronald J. Sokol, Binita M. Kamath. IBAT inhibitors in pediatric cholestatic liver diseases: Transformation on the horizon?. Hepatology 2024; doi: 10.1097/HEP.0000000000001032
|
| 5 |
A Current Understanding of Bile Acids in Chronic Liver Disease. Journal of Clinical and Experimental Hepatology 2022; 12(1): 155 doi: 10.1016/j.jceh.2021.08.017
|
| 6 |
Leon Deutsch, Alexandros Sotiridis, Boštjan Murovec, Janez Plavec, Igor Mekjavic, Tadej Debevec, Blaž Stres. Exercise and Interorgan Communication: Short-Term Exercise Training Blunts Differences in Consecutive Daily Urine 1H-NMR Metabolomic Signatures between Physically Active and Inactive Individuals. Metabolites 2022; 12(6): 473 doi: 10.3390/metabo12060473
|
| 7 |
Bandar D. Alrehaili. Unravelling the therapeutic landscape of bile acid-based therapies in gastrointestinal disorders. Saudi Journal of Gastroenterology 2024; 30(5): 283 doi: 10.4103/sjg.sjg_53_24
|
| 8 |
Rulaiha Taylor, Zhenning Yang, Zakiyah Henry, Gina Capece, Vik Meadows, Katherine Otersen, Veronia Basaly, Anisha Bhattacharya, Stephanie Mera, Peihong Zhou, Laurie Joseph, Ill Yang, Anita Brinker, Brian Buckley, Bo Kong, Grace L Guo. Characterization of individual bile acids in vivo utilizing a novel low bile acid mouse model. Toxicological Sciences 2024; 199(2): 316 doi: 10.1093/toxsci/kfae029
|
| 9 |
Gopanandan Parthasarathy, Harmeet Malhi, Jasmohan S. Bajaj. Therapeutic manipulation of the microbiome in liver disease. Hepatology 2024; doi: 10.1097/HEP.0000000000000987
|